Home » Products » VEGFR-PDGFR

Vascular endothelial growth factor receptor-Platelet derived growth factor receptor

Cat.No.	Product Name	Added

S1486	AEE788	Sep 2010
AEE788 is a novel multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.

S2221	Apatinib (YN968D1)	Apr 2011
Apatinib (YN968D1) is a small-molecule selective multitargeted tyrosine kinase inhibitor with an IC50 of 2.43 nM for the inhibition of VEGFR2.

S1207	AV-951(Tivozanib)	May 2010
AV-951 (Tivozanib) is a potent and selective VEGFR inhibitor to all three VEGF receptors, VEGFR-1, -2 and -3 with IC50 of 0.21 nM, 0.16 nM and 0.24 nM, respectively.

S1005	Axitinib	Apr 2009
Axitinib is a receptor kinase inhibitor with IC50 of 0.1 nmol (VEGFR-1), 0.2 nmol (VEGFR-2), 0.1–0.3 nmol (VEGFR-3), 1.6 nmol (PDGFR-β) and 1.7 nmol (c-KIT).

S1010	BIBF1120 (Vargatef)	Apr 2009
BIBF1120 (Vargatef) is a potent VEGF receptor (VEGFR), PDGFR and FGFR kinase inhibitor to VEGFR1, VEGFR2,VEGFR3 with IC50 of 34, 13 and 13 nM, respectively.

S2201	BMS 794833	Jan 2011
BMS794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.

S1084	Brivanib (BMS-540215)	Jul 2009
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.

S1138	Brivanib alaninate(BMS-582664)	Jan 2010
A multiple inhibitor of VEGFR( IC50 of VEGFR-2(25 nM), VEGFR-1 (380nM), VEGFR-3 (10 nM)); FGFR (FGFR-1 (IC50=148 nM), FGFR-2 (IC50 =125 nM), and FGFR-3 (IC50 = 68 nM))tyrosine kinases

S1017	Cediranib (AZD2171)	Apr 2009
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor to VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.

S2730	Crenolanib (CP-868569)	Dec 2011
Crenolanib (CP-868569) is a highly selective and potent PDGFR-α inhibitor with IC50 of 0.9 and 1.8 nM against PDGFRα and PDGFRβ, respectively.

S1171	CYC116	Apr 2010
CYC116 is an Aurora kinase/VEGFR2 inhibitor

S1018	Dovitinib (TKI258)	Apr 2009
Dovitinib (TKI258) is a highly potent, novel multitargeted growth factor receptor kinase inhibitor with IC50 of 1, 2, 5, 10, 8, 27, 36 nM for FLT3, c-KIT, FGFR, VEGFR1/2/3, PDGFRß and CSF-1R, respectively.

S1164	E7080	Feb 2010
Inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM)

S1111	Foretinib (GSK1363089, XL880)	Sep 2009
Foretinib (GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively.

S2475	Imatinib (Gleevec)	Feb 2011
Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.

S1026	Imatinib Mesylate	Apr 2009
Imatinib Mesylate is a multitargeted c-kit, PDGF-R and c-ABL inhibitor with IC50 of 3.9 and 2.9 μM for the inhibition of T-cell proliferation stimulated by DCs and PHA, respectively.

S1363	Ki8751	Jun 2010
Ki8751 is a potent, selective VEGFR-2 tyrosine kinase inhibitor with IC50 of 0.9 nM, 40, 67, 170 nM for VEGF-2, c-Kit, PDGFRα and FGFR-2, respectively.

S1557	KRN 633	Nov 2010
KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor with IC50 of 170 nM, 160 nM, and 125 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively.

S1003	Linifanib (ABT-869)	Apr 2009
Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor to human endothelial cells, PDGFR-β, KDR, and CSF-1R, with IC50 of 0.2, 2, 4, and 7 nM, respectively.

S1064	Masitinib	May 2009
Masitinib also known as Masivet, AB1010 is a tyrosine kinase, c-Kit, PDGFR, FGFR3, the FAK pathway inhibitor with IC50 of 150 ± 80, 200 ± 40 nM.

S1361	MGCD-265	Jun 2010
MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases.

S1032	Motesanib (AMG-706)	Apr 2009
Motesanib (AMG-706) is a multiple inhibitor of VEGFR1/2/3(IC50: 2 ηM /3 ηM /6 ηM),PDGFR (84ηM), kit (8ηM), and Ret (59ηM)receptors

S1244	MP-470	May 2010
MP-470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Met, c-Kit, PDGFRalpha, Flt3, and c-Ret and with an IC50 of median 5 μM.

S2202	NVP-BHG712	Mar 2011
NVP-BHG712 is a small molecule specific EphB4, VEGFR2, c-raf, c-src and c-Abl kinase inhibitor with ED50 of 25 nM, 4.2, 0.4, 1.3 and 1.7μM, respectively.

S1220	OSI-930	May 2010
OSI-930 is an inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).

S1035	Pazopanib	Apr 2009
Pazopanib is a VEGFR inhibitor, IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3.

S1264	PD173074	Jun 2010
PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, FGFR1 and VEGFR2, respectively.

S1490	Ponatinib (AP24534)	Sep 2010
Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN.

S2622	PP121	Jun 2011
PP121 is a multitargeted dual receptor tyrosine kinases inhibitor with IC50 of 0.052, 1.4, 0.15, 1.1, 0.06, 0.01and 0.002 μM for p110α, p110β, p110δ, p110γ, DNA-PK, mTOR and PDGFR, respectively.

S2161	RAF265 (CHIR-265)	Jan 2011
RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.

S2200	Raf265 derivative	Mar 2011
Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.

S1178	Regorafenib (BAY 73-4506)	Apr 2010
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.

S1040	Sorafenib (Nexavar)	May 2009
Sorafenib (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.

S1042	Sunitinib (Sutent)	May 2009
Sunitinib Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 µM for Flk-1 and PDGFR.

S2231	Telatinib (BAY 57-9352)	Apr 2011
Telatinib (BAY 57-9352) is an orally available, potent multitargeted VEGFR-2, VEGFR-3, PDGFR-β and c-Kit tyrosine kinases inhibitor with an IC50 of 19 nM for the inhibition of VEGFR-2 autophosphorylation.

S1470	TSU-68 (SU6668)	Aug 2010
TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 µM, 8 nM and 1.2 µM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively.

S1046	Vandetanib (Zactima)	Apr 2009
Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9 cells and tyrosine kinase activity, respectively.

S1101	Vatalanib (PTK787)	Aug 2009
Vatalanib (PTK787) is a novel VEGFR and c-Kit tyrosine kinases and angiogenesis inhibitor with IC50 of 0.037, 0.077, 0.27 and 0.73 μM for KDR, Flt-1, Flk and c-Kit, respectively.

S1119	XL184 (Cabozantinib)	Sep 2009
XL184 (Cabozantinib) is a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively.